In this article, we will be taking a look at the 10 Best Biotech Stocks to Buy Under $10.

The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC’s “Squawk Box” on July 25 to discuss various topics, including the current status of the biotech industry and what to expect from the earnings season.

She said that the biotech and healthcare industries have experienced several years of negative earnings revision cycles, and she wants to see these businesses now hitting the figures.

They have begun to show some steadiness, Richter continued, and Q2 is usually a stronger quarter. As a result, some biotech businesses in the sector could produce impressive financial outcomes.

According to the expert, launches and pipelines beyond statistics are two additional elements to consider in the sector.

She will continue to keep an eye on the several medicine launches that have occurred this year. Speaking of pipelines that go beyond statistics, she said that pain and Alzheimer’s disease have begun to receive attention this season.

With this in mind, let’s now take a look at the 10 best biotech stocks to buy under $10.  

Our Methodology 

For our methodology, we screened stocks with a share price below $10 and ranked them according to the number of hedge fund holders as of Q2 2025, based on data from the Insider Monkey database. Additionally, we included the share price as of the most recent closing (21 August) in the subheadings for clarity.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 10 best biotech stocks to buy under $10.  

10. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 14 

Share Price: $2.26 

ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotechnology company developing next-generation immunotherapies and cell therapies to treat cancer and infectious diseases, and is among the best biotech stocks. Its lead product, ANKTIVA, is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer (NMIBC), designed to activate NK cells, T cells, and memory T cells for durable disease control.

In June 2025, the FDA granted Expanded Access authorization for ImmunityBio, Inc. (NASDAQ:IBRX)’s Cancer BioShield™ platform, anchored by ANKTIVA, to treat lymphopenia in patients with relapsed or refractory solid tumors. These patients typically have critically low lymphocyte counts after standard treatments like chemotherapy or radiation. Data presented at the 2025 ASCO Annual Meeting showed that restoring lymphocytes in this group significantly prolongs survival, highlighting the company’s potential to address one of the most dangerous side effects of cancer therapy.

The business is also broadening its pipeline. In August 2025, it launched a Phase 2 trial of ANKTIVA for Long COVID, exploring immune modulation for post-infectious chronic disease. Additionally, the corporation initiated ResQ201A, a randomized trial combining N-803 (an interleukin-15 superagonist) with a PD-1 inhibitor for second-line non-small cell lung cancer, with plans for global expansion.

For papillary-only NMIBC, the FDA previously issued a Refuse-to-File letter on a supplemental BLA, but ImmunityBio, Inc. (NASDAQ:IBRX) is resubmitting updated long-term trial data showing encouraging outcomes with ANKTIVA plus BCG. The company is also engaging with regulators to update clinical guidelines that could expand access for more bladder cancer patients.

9. AbCellera Biologics Inc. (NASDAQ:ABCL)

Number of Hedge Fund Holders: 17 

Share Price: $4.17 

AbCellera Biologics Inc. (NASDAQ:ABCL) is a Canadian biotechnology company using its antibody discovery platform to develop therapies for cancer, autoimmune, metabolic, and endocrine disorders. Long recognized for industry partnerships, the company is now advancing into clinical development with proprietary assets.

In August 2025, AbCellera Biologics Inc. (NASDAQ:ABCL) dosed the first participants in a Phase 1 trial of ABCL635, a non-hormonal antibody therapy targeting the neurokinin 3 receptor (NK3R) for vasomotor symptoms of menopause, such as hot flashes. Current treatments are largely hormone-based, making this candidate a potential breakthrough for millions of women seeking safer, long-acting alternatives. The trial will evaluate safety, pharmacokinetics, and pharmacodynamics in both healthy participants and postmenopausal women.

AbCellera Biologics Inc. (NASDAQ:ABCL) also received Health Canada approval to begin a Phase 1 trial of ABCL575, an antibody antagonist of OX40 ligand (OX40L) for atopic dermatitis and other inflammatory conditions. Preclinical data suggest it could inhibit T cell–mediated inflammation with extended dosing intervals, potentially improving efficacy and convenience for patients.

8. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 21 

Share Price: $4.77 

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug discovery. Its proprietary platform, Recursion OS, is central to advancing therapies in oncology and rare diseases.

In 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) partnered with MIT to launch Boltz-2, an AI model trained on its BioHive-2 platform to predict small molecule–protein binding with high precision. This breakthrough could shorten drug discovery timelines and strengthen its leadership in AI-driven bioengineering. The business also rolled out Recursion OS 2.0 and expanded collaborations with Tempus and HealthVerity to leverage multimodal datasets.

A major strategic shift came with the merger with Exscientia, combining Exscientia’s small molecule design expertise and pipeline with the firm’s AI platform. This transformative move highlights why RXRX is often included among the best biotech stocks, given its strong positioning in AI-enabled drug discovery. To streamline operations, the company discontinued several programs and focused on six core candidates, four in oncology and two in rare diseases. Lead programs include REC-617, a CDK7 inhibitor in cancer, and REC-4881, targeting familial adenomatous polyposis.

In July 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) expanded its rare disease pipeline by acquiring REV102, an oral ENPP1 inhibitor for hypophosphatasia (HPP), a disorder with no existing oral treatments. This positions the corporation to address a critical unmet need.

With multiple clinical trial initiations and data readouts expected in late 2025, alongside its strengthened AI capabilities and partnerships with global pharma leaders like Roche, Sanofi, Bayer, and Merck KGaA, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is positioned as a frontrunner in AI-driven drug discovery and development.

7. Novavax, Inc. (NASDAQ:NVAX)

Number of Hedge Fund Holders: 24 

Share Price: $8.74 

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company specializing in recombinant protein-based vaccines, using protein nanoparticles and the proprietary Matrix-M adjuvant to elicit strong and broad immune responses. The company focuses on addressing unmet needs in infectious disease prevention, offering alternatives to mRNA vaccines, and advancing innovative vaccine R&D.

In May 2025, Novavax, Inc. (NASDAQ:NVAX) received full FDA approval for Nuvaxovid™, its protein-based COVID-19 vaccine, the only non-mRNA option currently available in the U.S. The initial indication covers adults 65+ and high-risk individuals aged 12–64. Following this milestone, the company transferred U.S. commercial leadership of Nuvaxovid™ to Sanofi, with authorization transfers for the U.S. and EU expected by the end of 2025. The partnership aims to broaden distribution, streamline logistics, and generate milestone payments for the corporation.

The business is advancing late-stage candidates, including a COVID-19–Influenza Combination vaccine and a stand-alone seasonal influenza vaccine. Early Phase 3 data show robust immune responses and improved T-cell activation compared with Fluzone HD. These programs remain unpartnered but are under active discussion with potential collaborators.

The Matrix-M adjuvant enhances immune response while allowing lower antigen doses, reducing manufacturing costs and simplifying distribution, especially in regions with limited cold-chain infrastructure. Novavax, Inc. (NASDAQ:NVAX) is also advancing novel vaccines, including a bird flu candidate in collaboration with public health agencies, positioning the company as a key player in pandemic preparedness.

Full handover to Sanofi in the U.S. and EU is expected in Q4 2025, expanding vaccine reach and production. Ongoing late-stage pipeline development and partnering efforts highlight the firm’s shift from R&D focus to broader commercialization and global distribution, leveraging its unique position as a non-mRNA vaccine provider in Western markets.

6. MiMedx Group, Inc. (NASDAQ:MDXG)

 Number of Hedge Fund Holders: 25 

Share Price: $7.17 

MiMedx Group, Inc. (NASDAQ:MDXG) is a biotechnology company based in Marietta, Georgia, specializing in regenerative biologics for advanced wound care and surgical recovery. Its portfolio, developed through the patented PURION process, includes EPIFIX, AMNIOFIX, CELERA™, and EMERGE™, which are widely used in chronic wound management and surgical applications.

MiMedx Group, Inc. (NASDAQ:MDXG) reported a record Q2 2025 with 13% year-over-year net sales growth, driven by strong performance in both Wound and Surgical categories. New products CELERA™ and EMERGE™ saw rapid adoption, while established products AMNIOFIX and AMNIOEFFECT delivered double-digit growth. With its consistent execution and innovative pipeline, the company is increasingly being recognized among the best biotech stocks for investors seeking growth in the regenerative medicine space.

The company also entered a strategic partnership with Vaporox, Inc., integrating its placental allografts with Vaporox’s FDA-cleared Vaporous Hyperoxia Therapy (VHT) device. Targeting difficult-to-heal chronic wounds such as diabetic foot and pressure ulcers, the combination therapy has shown healing rates above 80% at 20 weeks, outperforming standard treatments and demonstrating significant innovation in wound care.

On the policy front, the Centers for Medicare and Medicaid Services (CMS) proposed reimbursement reforms for skin substitutes in July 2025. MiMedx Group, Inc. (NASDAQ:MDXG) has welcomed the changes, emphasizing patient care and cost efficiency, while maintaining active engagement with regulators to shape evolving standards.

5. MannKind Corporation (NASDAQ:MNKD)

Number of Hedge Fund Holders: 26 

Share Price: $3.97 

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company developing inhaled therapeutic products for endocrine and orphan lung diseases. Its flagship product, Afrezza, is a rapid-acting inhaled insulin, and the company’s pipeline includes therapies for rare lung conditions such as nontuberculous mycobacterial (NTM) lung disease and idiopathic pulmonary fibrosis (IPF).

MannKind Corporation (NASDAQ:MNKD) submitted a supplemental Biologics License Application (sBLA) to the FDA to expand Afrezza use to pediatric patients aged 4–17. This submission is supported by positive Phase 3 INHALE-1 trial data demonstrating safety and efficacy in children, with a regulatory decision expected in Q4 2025.

The business is advancing its orphan lung disease portfolio. MNKD-101, an inhaled clofazimine for NTM lung disease, is enrolling ahead of schedule in its global Phase 3 ICoN-1 trial, while MNKD-201, targeting IPF, is planned to enter Phase 2 trials by year-end.

The corporation secured up to $500 million in non-dilutive financing to support the pediatric Afrezza rollout, expand commercial capabilities, and accelerate clinical programs. The company is also exploring artificial intelligence to optimize product delivery systems, enhancing operational efficiency and patient outcomes.

The U.S.-based manufacturing facility in Danbury, Connecticut, supports both revenue generation and pipeline production, minimizing supply chain risks. MannKind Corporation (NASDAQ:MNKD)’s revenue is further strengthened by royalties from Tyvaso DPI, an inhaled therapy for pulmonary arterial hypertension developed in partnership with United Therapeutics.

4. Ardelyx, Inc. (NASDAQ:ARDX)

Number of Hedge Fund Holders: 27 

Share Price: $5.99 

Ardelyx, Inc. (NASDAQ:ARDX) stands fourth on our list among the best biotech stocks. It is a biopharmaceutical company developing therapies for gastrointestinal and cardiorenal diseases, with FDA-approved treatments IBSRELA (tenapanor) for IBS-C and XPHOZAH (tenapanor) for hyperphosphatemia in dialysis patients. The company has established itself as a promising small-cap biotech with strong commercial traction.

Ardelyx, Inc. (NASDAQ:ARDX) reported record prescription volumes and net sales growth in Q2 2025, with revenues reaching $97.7 million, surpassing expectations. IBSRELA sales increased 57% year-over-year in Q1, and XPHOZAH also showed strong growth. The firm raised its 2025 sales guidance for IBSRELA to $250–$260 million, reflecting robust market uptake and physician adoption. This momentum supports investor confidence and positions the company for sustainable revenue growth.

The corporation strengthened its leadership team with executive appointments, including Edward Conner as Chief Medical Officer and John Bishop as Chief Technology and Operating Officer, signaling readiness to accelerate development and commercialization. The company also pursues international expansion through partnerships, such as with Kyowa Kirin, to broaden tenapanor’s global reach.

While growth is currently driven by IBSRELA and XPHOZAH, Ardelyx, Inc. (NASDAQ:ARDX) continues to invest in R&D to address unmet medical needs in gastrointestinal and related conditions.

3. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Number of Hedge Fund Holders: 31 

Share Price: $7.57 

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a Chicago-based commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Its key products include Recorlev for Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis, with a promising pipeline candidate, XP-8121, in Phase 3 for hypothyroidism.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) reported record Q2 2025 revenue of $71.5 million, a 49% year-over-year increase, with Recorlev sales surging 136%. This strong performance prompted the company to raise its 2025 revenue guidance to $280–$290 million.

In June 2025, the business held its first Analyst and Investor Day, presenting a long-term growth vision targeting $750 million total revenue by 2030 and $1–$3 billion peak net revenue from XP-8121 by 2035. The company is expanding its commercial infrastructure while investing in pipeline innovation, signaling confidence in sustaining growth through existing therapies and future product launches.

While Recorlev drives immediate revenue growth, XP-8121 offers potential diversification and long-term revenue expansion. The dual focus on commercial execution and clinical advancement positions Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) as a competitive player in the biotech sector, with transformative potential in endocrine disease treatment.

2. Wave Life Sciences Ltd. (NASDAQ:WVE)

Number of Hedge Fund Holders: 36 

Share Price: $9.45 

Wave Life Sciences Ltd. (NASDAQ:WVE) is a Singapore-based clinical-stage biotechnology company developing RNA-based therapies using its proprietary PRISM platform. The company targets rare and prevalent diseases, including alpha-1 antitrypsin deficiency (AATD), Duchenne muscular dystrophy (DMD), Huntington’s disease, and obesity.

Wave Life Sciences Ltd. (NASDAQ:WVE) reported promising preclinical results for WVE-007, an obesity candidate that modulates the INHBE gene to reduce fat, preserve muscle, and promote healthy weight loss, presented at the American Diabetes Association’s Annual Scientific Sessions.

Clinical progress includes positive data from the FORWARD-53 trial with WVE-N531 for DMD, showing functional improvement and reversal of muscle damage after 48 weeks. Early human trial results for WVE-006 in AATD demonstrated significant increases in AAT protein levels after a single low dose, reaffirming the business’s potential in RNA editing therapies. These milestones have strengthened investor confidence and led to analyst upgrades.

Despite challenges such as quarterly sales declines and higher net losses due to heavy R&D investment, Wave Life Sciences Ltd. (NASDAQ:WVE) is advancing multiple RNA-based programs toward pivotal trials. The obesity candidate WVE-007 represents a potential new revenue stream, reducing reliance on collaboration revenue.

1. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Number of Hedge Fund Holders: 40 

Share Price: $7.40 

Amicus Therapeutics, Inc. (NASDAQ:FOLD) tops our list for being one of the best biotech stocks. It develops therapies for rare diseases, including Fabry disease and late-onset Pompe disease. Its flagship products include Galafold, an oral precision medicine for Fabry disease, and the combination therapy Pombiliti + Opfolda for Pompe disease.

The company recently acquired DMX-200, a candidate targeting focal segmental glomerulosclerosis (FSGS), broadening its rare disease portfolio and strengthening long-term growth potential beyond current products. This expansion enhances diversification and mitigates risks associated with portfolio concentration.

Despite a year-over-year net loss in Q2 2025, Amicus Therapeutics, Inc. (NASDAQ:FOLD) reaffirmed guidance for 15–22% total revenue growth and anticipates positive GAAP net income in the second half of 2025. Strong sales traction for Galafold and growing adoption of Pombiliti + Opfolda are key drivers of this revenue growth.

Analysts remain positive on Amicus Therapeutics, Inc. (NASDAQ:FOLD), with price targets between $13 and $20, reflecting potential upside from its expanding rare disease franchise, pipeline development, and improving profitability. Firms like TD Cowen and Guggenheim maintain Buy ratings, highlighting the corporation’s strategic positioning and growth prospects.

While we acknowledge the potential of FOLD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than FOLD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.